

- (a) providing a population of host cells according to claim 79; and  
(b) culturing said population of cells under conditions whereby the polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

86. (New) A method of producing a recombinant polypeptide comprising:

- (a) providing a population of host cells according to claim 80; and  
(b) culturing said population of cells under conditions whereby the polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

87. (New) A method of producing a recombinant polypeptide comprising:

- (a) providing a population of host cells according to claim 81; and  
(b) culturing said population of cells under conditions whereby the polypeptide encoded by the coding sequence present in said recombinant vector is expressed.

88. (New) A method of producing a recombinant polypeptide comprising:

- (a) providing a population of host cells according to claim 82; and  
(b) culturing said population of cells under conditions whereby the polypeptide encoded by the coding sequence present in said recombinant vector is expressed. )

#### REMARKS

Claims 42 and 50 have been amended and new claims 57-88 have been added by way of this Third Preliminary Amendment. A copy of the currently elected claims, incorporating the amendments made herein, is included for the Examiner's convenience.

In particular, claim 42 has been amended to clarify that the three recited CDRs are present in an "ordered arrangement." Support for this amendment can be found throughout the specification at, e.g., page 29, line 15; and page 36, lines 21-22. Moreover, claim 42 now recites that the CDRs have sequences with "at least 70%

sequence identity” to the reference sequence. Support for this recitation may be found at, e.g., page 10, lines 9-21. Claim 50 has been amended to recite the invention with greater particularity.

The new claims are directed to subject matter belonging to elected Group II as set forth in the Restriction Requirement. Specifically, all of the new claims recite individual members of the Markush Group specified in elected claim 42. Accordingly, the new claims properly belong with the elected subject matter. In particular, new claims 57-63, 71-73, 77-79 and 83-85 pertain to DNA molecules, recombinant vectors, host cells and methods of recombinant production, respectively, which include sequences for CDRs from antibody 520C9. New claims 64-70, 74-76, 80-82 and 86-88 pertain to DNA molecules, recombinant vectors, host cells and methods of recombinant production, respectively, which include sequences for CDRs from antibody 741F8. Additional support for the recitations in the new claims can be found throughout the specification, at, for example, page 6, lines 6-7; page 6, lines 17-29; page 8, lines 24-29; page 9, lines 22-24; page 10, line 22; page 36, lines 18-19; and page 36, lines 21-23.

No new matter has been added by way of this amendment and entry thereof is respectfully requested.

#### **CONCLUSION**


Applicant respectfully submits that the claims comply with the requirements of 35 U.S.C. §112 and define an invention that is patentable over the art. Accordingly, a Notice of Allowance is believed in order and is respectfully requested.

Please direct all further written communications regarding this application to the following address:

Joseph H. Guth, Esq.  
Chiron Corporation  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097.

Respectfully submitted,

Date: 12/28/00

By:   
Roberta L. Robins  
Registration No. 33,208  
Attorney for Applicants

ROBINS & ASSOCIATES  
90 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 325-7812  
Facsimile: (650) 325-7823